AngelaY.MooreMD

Dermatology • Arlington, TX

Acne & Rosacea, Dermatopathology

Physician

Join to view full profile

Dr. Moore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moore's full profile

Already have an account?

Office
711 E Lamar Blvd
Ste 200
Arlington, TX 76011
Phone+1 817-795-7546

Fax+1 817-226-7546

Education & Training

University of Texas Medical Branch HospitalsFellowship, Dermatopathology, 1996 - 1997
University of Texas Medical Branch HospitalsResidency, Dermatology, 1993 - 1996
University of Texas Medical Branch HospitalsInternship, Internal Medicine, 1992 - 1993
Baylor College of MedicineClass of 1992

Certifications & Licensure

TX State Medical License 1993 - 2025
American Board of Dermatology Dermatology
American Board of Dermatology Dermatopathology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
Completed
Phase 2
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 Mar 01
Completed
Phase 3
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 May 01
Completed
Phase 3
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 4
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis Start of enrollment: 2022 Jun 07
Terminated
Phase 2
Roles: Contact
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

10 citations
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia
Journal of the American Academy of Dermatology. 2024-05-01
5 citations
Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: A retrospective study.
Angela Yen Moore, Madalyn Nguyen, Stephen Moore
Journal of the American Academy of Dermatology. 2021-04-01
5 citations
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani
The British Journal of Dermatology. 2023-09-15

Press Mentions

Narrow Spectrum Tetracycline for Moderate-to-Severe AcneOctober 11th, 2019
Novel Oral Antibiotic Treatment Seysara™ (Sarecycline) Now AvailableJanuary 17th, 2019
Almirall's Seysara Now AvailableJanuary 17th, 2019

Professional Memberships

American Academy of Dermatology - AAD
Fellow

Other Languages

Spanish, Chinese (Mandarin)

External Links

Arlington Center for Dermatologyhttp://acderm.com/ACD-WP/